Comparing Efficacy Between Anti-microtubule and Non-anti-microtubule as 3th Therapy After 2nd Line EGFR-TKI Therapy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00836160

Enrollment

Registered

2009-02-04

Start date

2009-08-31

Completion date

2012-09-30

Last updated

2012-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Keywords

EGFR-TKI therapy, NSCLC, Efficacy

Brief summary

This is an observational prospective study that investigates only daily practice. The prescription of anti-cancer medicine is separated from the decision to include the patient in this study. In addition, the assignment of the patient to a particular therapy or therapeutic strategy is not decided in advance by this study protocol, but falls within current practice. The patient who fulfils eligible criteria will be enrolled when starts to receive the second-line EGFR-TKI therapy. The frequency of tumor response evaluation by RECIST criteria follows the investigator's discretion as daily practice.

Interventions

None listed

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* At least one measurable lesion according to RECIST criteria * Histologically or cytologically confirmed NSCLC of adeno histology * Locally progressed or metastasized on or after first-line chemotherapy. The imaging evidence of disease progression can be either chest X ray, CT or MRI assessment on measurable lesions. If no measurable lesion is available, evaluable lesions are acce

Exclusion criteria

Design outcomes

Primary

Measure	Time frame
PFS of the third-line therapy	9 months

Secondary

Measure	Time frame
Overall objective tumor response (complete response [CR] + partial response [PR]) of the third-line therapy by RECIST criteria	9 months

Countries

Taiwan

Outcome results